clinical trial · NCT05376176
A Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared With Vehicle in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD)
Fuchs Endothelial Corneal DystrophySTN1010904 ophthalmic suspension 0.03% BIDSTN1010904 ophthalmic suspension 0.1% BIDPlacebo (Vehicle) BID
brief summary
This is a Phase IIa study to assess efficacy and safety of STN1010904 ophthalmic suspension (0.03%, and 0.1 %), twice daily dosing when compared to Placebo in subjects diagnosed with Fuchs Endothelial Corneal Dystrophy (FECD). This study will consist of a Screening Period of up to 15 days and an 18-month Double-Masked Treatment Period, including 9 individual visits to the study site.
started
May 19, 2022
primary completion
May 26, 2025
completion
May 26, 2025
last updated
Jul 15, 2025
official title
A Phase IIa, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared With Vehicle in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD) - PHANTOM Study
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol